BLK vs LLY: Which Is the Better Buy?
Side-by-side comparison of BlackRock, Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
BlackRock, Inc. · Financial Services
$1,042.85
+36.5% upside to fair value
Grade A
High Quality
VS
Eli Lilly and Company · Healthcare
$934.34
+17.6% upside to fair value
Grade B
High Quality
QuantHub Verdict
BLK has more upside to fair value
(+36.5%).
BLK trades at a lower forward P/E
(25.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
BLK |
LLY |
| Current Price |
$1,042.85 |
$934.34 |
| Fair Value Estimate |
$1,423.18 |
$1,098.43 |
| Upside to Fair Value |
+36.5%
|
+17.6%
|
| Market Cap |
$162.2B |
$882.8B |
| Forward P/E |
25.9x
|
33.1x
|
| EV / EBITDA |
16.9x
|
27.9x
|
| Price / Sales |
6.3x
|
12.2x
|
| Price / FCF |
45.2x
|
65.0x
|
| Revenue Growth YoY |
+28.3%
|
+55.5%
|
| Gross Margin |
59.1%
|
82.7%
|
| Operating Margin |
29.9%
|
46.3%
|
| Return on Equity |
12.0%
|
101.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.21%
|
1.54%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
BlackRock, Inc. is the world's largest asset manager with over $14 trillion in assets under management, operating primarily in financial services and asset management. The company benefits from a durable competitive moat driven by its scale, technology platform Aladdin, and founder-led management with CEO Laurence D. Fink at the helm since inception. BlackRock exhibits strong fundamentals includi…
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Accumulation Zones
| Metric |
BLK |
LLY |
| Zone Low |
$1,067.38 |
$823.82 |
| Zone High |
$1,209.70 |
$933.67 |
| In Buy Zone? |
Yes
|
No
|